Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
NCT01983124
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Malignant Melanoma Stage IV
Interventions
DRUG:
Fotemustine + Vemurafenib
Sponsor
Paola Queirolo
Collaborators
[object Object]